The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

In an exclusive interview, Anne and Janet Wojcicki share how their family is working to raise awareness and fund research ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...

A drug used to help Canadians lose weight has now been approved to reduce the risk of non-fatal heart attacks. Novo Nordisk ...

Health Canada has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...